AbbVie Inc. Q3 2026 Earnings Recap

AbbVie’s shares rose 1.3%, a roughly flat reaction, as third-quarter revenue and adjusted EPS came in above the company’s expectations and full-year revenue guidance increased. Skyrizi and Rinvoq drove immunology growth, while the call also highlighted continued Humira sales declines.

Key Takeaways

• Third-quarter revenue was $17.4 billion, up more than 10%; adjusted EPS was $3.82, $0.07 above the company’s guidance midpoint.
• AbbVie raised full-year revenue guidance by $200 million, bringing the total increase since the start of the year to $800 million.
• Immunology revenue approached $9.2 billion, up 16.6% operationally. Skyrizi sales were nearly $5.8 billion, up 22.9%, and Rinvoq sales were $2.7 billion, up 24.3%.
• Humira sales were $683 million, down 30%.
• The company announced a 5.2% increase in its quarterly dividend, beginning with the payment in February 2027.